Omnicef generic or cefdinir is a broad spectrum antibiotic drug for adult and pediatric use. It is indicated for the treatment of community-acquired pneumonia, acute bacterial sinusitis, acute exacerbation of chronic bronchitis, pharyngitis and uncomplicated skin and skin structure infections. In children, the antibiotic drug is used for the management of middle ear infections. The adult formulation of Cefdinir 300 mg capsule whereas for paediatrics, a pleasant tasting strawberry suspension is available.
Omnicef Generic and Its Uses
The name of Omnicef generic is Cefdinir which is a cephalosporin antibiotic drug used to treat a wide variety of bacterial infections. The medicine is specially formulated to stop the growth of the bacteria. It is to notify the antibiotic drug treats only bacterial infections. It will not be effective against viral infections like cold and flu. Using an antibiotic medication like cefdinir when it is not needed can cause it to not work for future infections.
Instructions to use Omnicef Generic
Take Cefdinir with or without food, it’s usually taken once or twice a day to treat the bacterial infections. The dosage is based on your medical conditions and response to the antibiotic therapy. To achieve the best results, take the medicine at evenly spaced times. Complete the full course even if your symptoms disappear after using the drug for a few days. Sudden discontinuation before the prescribed time may allow bacteria to grow, which may result in a relapse of the infection.
Side Effects
The medicine is proven and well tolerated in clinical trials. Most commonly reported side effects involved the gastrointestinal tract infections. The drug should not be used with a known allergy to the cephalosporin class of antibiotics.
Marie
Latest posts by Marie (see all)
- Everything About Albuterol Inhaler: Uses, Benefits, and How It Works - November 14, 2024
- Understanding Combivent Inhaler: Uses, Benefits, and How It Works - November 5, 2024
- Ciprofloxacin Eye Drops 3% Dosage for Adults - November 4, 2024